Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial
Marı́a Buti(Vall d'Hebron Hospital Universitari), Edward Gane(Auckland Institute of Studies), Wai Kay Seto(Queen Mary Hospital), Henry Lik‐Yuen Chan(Chinese University of Hong Kong), Wan‐Long Chuang(Kaohsiung Medical University Chung-Ho Memorial Hospital), T. E. Stepanova(Moscow Institute of Modern Business), Aric-Josun Hui(Alice Ho Miu Ling Nethersole Hospital), Young‐Suk Lim(Asan Medical Center), Rajiv Mehta(Institute of Medical Sciences), Harry L.A. Janssen(Toronto Liver Centre), Subrat Kumar Acharya(All India Institute of Medical Sciences), John F. Flaherty(Gilead Sciences (United States)), Benedetta Massetto(Gilead Sciences (United States)), Andrea L. Cathcart(Gilead Sciences (United States)), Kyungpil Kim(Gilead Sciences (United States)), Anuj Gaggar(Gilead Sciences (United States)), G. Mani Subramanian(Gilead Sciences (United States)), John G. McHutchison(Gilead Sciences (United States)), Calvin Q. Pan(NYU Langone Health), Maurizia Rossana Brunetto(Azienda Ospedaliera Universitaria Pisana), Namiki Izumi(Musashino Red Cross Hospital), Patrick Marcellin(Hôpital Beaujon)
Cited by 543
Abstract
Related Papers
No related papers found
Powered by citation graph analysis